Andrew Baum
Stock Analyst at Citigroup
(3.57)
# 890
Out of 4,761 analysts
62
Total ratings
72.09%
Success rate
12.89%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $89.50 | +28.49% | 13 | Feb 5, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $26.30 | +10.27% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $55.83 | +16.42% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $33.42 | +19.69% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $202.08 | +6.39% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $873.68 | +2.44% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $12.28 | -18.57% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $36.64 | - | 2 | Jul 5, 2017 |
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $89.50
Upside: +28.49%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $26.30
Upside: +10.27%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $55.83
Upside: +16.42%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $33.42
Upside: +19.69%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $202.08
Upside: +6.39%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $873.68
Upside: +2.44%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $12.28
Upside: -18.57%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $36.64
Upside: -